As a new-type foreign trade service provider driven by dual engines of technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory sources of EPH from multiple well-known brands.
As a research-and-development-oriented foreign trade enterprise, HiSiaddi is not limited to promoting a single brand’s proprietary technology. We objectively analyze multiple domestic and international leading brands with large market share and share their latest major process advancements and breakthroughs, enabling purchasers to access authentic, up-to-date market information.
If you require more comprehensive and valuable EPH market intelligence, please contact HiSiaddi customer service.
1.
Breakthrough Details Huangma, Yida, and Wanhua have simultaneously launched titanium silicalite molecular sieve green catalytic production lines, replacing traditional high-temperature chloroethanol condensation processes. The single-pass conversion rate of phenol raw materials has risen from the traditional 78% to 92.7%; generation of byproducts anisole and diphenyl ether has decreased by 36%. Comprehensive energy consumption per unit product has fallen by 38.2%, while production wastewater COD has dropped from the original 850 mg/L to ≤125 mg/L, exceeding the EU REACH wastewater control limit of 500 mg/L. Demei and Feixiang have completed catalytic rectification technical upgrades for existing facilities, boosting rectification yield by 4.1 percentage points and reducing rectification residual liquid discharge by 42%.
2.
3.
Benefits for Purchasers ① Lower total raw material impurities reduce sediment accumulation during buyer warehousing, eliminating pre-treatment steps and cutting formula processing energy consumption by 6%–9%; ② Products meet EU environmental traceability audit standards, compatible with carbon footprint accounting for European and North American beauty brands, removing additional environmental testing premiums for importers; ③ Reduced production costs for domestic manufacturers stabilize pricing for bulk long-term procurement, compressing quarterly quotation fluctuations within ±3%.
4.
1.
Breakthrough Details All five leading manufacturers have fully realized mass production of graded high-purity EPH: cosmetic grade purity ≥99.92%, pharmaceutical grade purity ≥99.95%. The critical harmful impurity free phenol limit has been drastically reduced from the conventional ≤20 ppm to ≤3 ppm (EP pharmacopoeia upper limit: 5 ppm), with heavy metals (lead, arsenic, cadmium) controlled at ≤0.1 ppm. Demei took the lead in obtaining mass production qualifications for USP & EP dual pharmacopoeia certified pharmaceutical-grade EPH, filling the gap in domestic pharmaceutical-grade EPH pharmacopoeia indicators. Wanhua developed electronic-grade special EPH with water content ≤0.03%, suitable for semiconductor cleaning agent niche applications.
2.
3.
Benefits for Purchasers ① Cosmetic buyers can directly apply the material to sensitive skin and maternal & infant care formulas without additional impurity removal auxiliary agents, cutting overall formula costs by 5%–8%; ② Pharmaceutical preparation manufacturers meet compliance requirements for eye drops and multi-dose injection preservatives without switching to imported alternative raw materials; import substitution for vaccine excipients reduces procurement costs by 18%–25% versus European and American raw materials; ③ Mitigate risks of non-compliance during global beauty regulatory sampling inspections and lower product recall probabilities.
4.
1.
Breakthrough Details Huangma and Demei jointly developed microcapsule coated phenoxyethanol with D50 particle size 8.2–8.5 μm and effective ingredient encapsulation rate ≥92.4%, achieving 10,000-ton annual mass production in 2025. The modified product delivers a 72% reduction in instantaneous skin irritation; antiseptic slow-release duration extends from the standard 3 months to 6 months, with required formula addition dosage reduced from 1% to 0.5% while maintaining equivalent antiseptic efficacy.
2.
3.
Benefits for Purchasers ① Manufacturers of sensitive skincare and medical aesthetic dressings drastically reduce end-user sensitization complaints and improve finished product inspection pass rates; ② Lower preservative addition dosage simplifies formula systems and reduces finished goods raw material inventory categories; ③ Premium pricing for microcapsule EPH remains controllable, with a unit price 12% lower than equivalent imported modified products.
4.
1.
Breakthrough Details Feixiang and Yida optimized standardized compounding processes for EPH + ethylhexylglycerin. Precisely proportioned blends deliver a 39% improvement in broad-spectrum antibacterial efficiency, cutting kill time for Pseudomonas aeruginosa and Candida albicans by 50%. The compound product is colorless and odorless, compatible with fragrance-free washing and color cosmetic formulas.
2.
3.
Benefits for Purchasers Buyers can directly source pre-compounded finished products, eliminating independent batching and homogenization steps, cutting production working hours by 15% and shortening formula R&D cycles by 30%.
4.
1.
Breakthrough Details In 2026, Clariant launched Phenoxetol™ SG bio-based phenoxyethanol, utilizing bio-fermented ethanol instead of fossil feedstock with a Renewable Carbon Index (RCI) of 25%. Its chemical structure and antiseptic performance match fully petroleum-based EPH. The product achieves 68% biodegradation within 28 days per OECD301B testing, exceeding the industry average of 52% for conventional products, with an expanded full-formula pH compatibility range of 3.0–8.8.
2.
3.
Benefits for Purchasers European and American natural beauty brands may apply natural raw material labeling based on bio-based parameters, lifting end-product premium margins by 8%–12%. Formulas require no reworking, with existing production equipment directly usable at zero modification cost. The product complies with EU carbon tax regulations, enabling importers to qualify for partial carbon import tariff reductions.
4.
1.
Breakthrough Details BASF’s Ludwigshafen base and Dow’s Freeport (USA) facility completed upgrades to closed-loop automated gas-phase etherification continuous production units. Batch purity fluctuation has narrowed from ±0.15% to ±0.03%, with fluctuations in trace impurity byproducts reduced by 80%. Pharmaceutical-grade batch impurity consistency meets FDA continuous batch quality control standards. Optimized co-production feedstock modes boost ethylene oxide raw material utilization by 5.3%.
2.
3.
Benefits for Purchasers Multinational daily chemical groups with multi-site unified formula production experience a 90% reduction in finished product scrap rates caused by batch raw material differences. Global pharmaceutical enterprises operating multiple formulation factories can adopt a single standardized raw material, simplifying multi-country drug regulatory filing workflows.
4.
1.
Breakthrough Details Iterated rectification and refining processes from LANXESS produce ophthalmic-grade ultra-high-purity EPH with residual irritant ethylene oxide controlled at ≤0.2 ppm (industry standard ≤2 ppm). Rabbit eye irritation score ≤0.5, meeting European and American ophthalmic excipient access standards.
2.
3.
Benefits for Purchasers Pharmaceutical manufacturers producing eye drops and nasal sprays eliminate the need for additional raw material refining; excipient safety passes FDA/CE certification in a single step, shortening new drug filing cycles.
4.
1.
Breakthrough Details Self-developed low-temperature membrane separation purification technology avoids yield loss from high-temperature rectification, lifting high-purity cosmetic-grade EPH yield by 6.8% and reducing production energy consumption by 29%. Residual phenol is controlled at ≤4 ppm, matching mid-tier high-purity indicators of European and American brands.
2.
3.
Benefits for Purchasers Small and medium-sized beauty manufacturers in Southeast Asia and the Middle East can source cost-effective high-purity raw materials balancing compliance and budget. Replacing low-quality crude industrial material raises end-product cross-border inspection pass rates.
4.
1. Compliance Benefits All leading domestic and international manufacturers have completed full certification upgrades including REACH, FDA, ISO22716, and GMP. A single raw material order enables customs clearance across all major regions (Europe, America, Southeast Asia, Japan & South Korea), eliminating the need for separate multi-specification raw material inventory for different jurisdictions.
2. Formula Benefits Full product lines have undergone low-impurity and low-irritation upgrades, enabling full domestic substitution and affordable imported alternatives for three high-barrier application sectors: maternal & infant care, medical aesthetic products, and injectable pharmaceutical excipients.
3. Supply Chain Benefits Domestic green process cost reductions complement differentiated bio-based overseas products. Purchasers may select grades segmented by premium natural lines, mass-market daily chemical lines, and pharmaceutical lines to optimize raw material procurement cost structures.
For more comprehensive and valuable EPH market intelligence, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
